Relatório global de análise do tamanho, quota e tendências do mercado de válvulas cardíacas protéticas – Visão geral do setor e previsão para 2031

Análise do mercado de válvula cardíaca protética

O mercado das válvulas cardíacas protéticas está a registar um crescimento constante impulsionado por uma prevalência crescente de doenças cardiovasculares e pelos avanços nas técnicas de cirurgia cardíaca. As próteses cardíacas são cruciais no tratamento de condições como a estenose valvular e a regurgitação, que podem prejudicar gravemente a função cardíaca se não forem tratadas. Por exemplo, um artigo de 2021 publicado pela Biblioteca Nacional de Medicina indicou que mais de 180.000 cirurgias de substituição de válvulas cardíacas são realizadas todos os anos nos EUA, contribuindo significativamente para o crescimento do mercado de substituições de válvulas cardíacas. Espera-se que os esforços contínuos de investigação e desenvolvimento, juntamente com a crescente consciencialização sobre a saúde cardiovascular e as opções de tratamento, sustentem o crescimento do mercado.

Tamanho do mercado de válvulas cardíacas protéticas

O tamanho global do mercado de válvulas cardíacas protéticas foi avaliado em 6,96 mil milhões de dólares em 2023 e deverá atingir os 14,69 mil milhões de dólares até 2031, com um CAGR de 9,79% durante o período de previsão de 2024 a 2031. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços e enquadramento regulamentar.

Âmbito do relatório e segmentação de mercado       

Prosthetic Heart Valve Market Definition

A prosthetic heart valve is a synthetic device surgically implanted to replace a damaged or diseased natural heart valve. It serves to restore proper blood flow through the heart, mimicking the function of the original valve. Prosthetic heart valves come in two primary types: mechanical and biological. Prosthetic heart valves play a crucial role in treating heart valve diseases, restoring cardiac function, and improving patients' quality of life.          

Prosthetic Heart Valve Market Dynamics

Drivers

• Increasing Prevalence of Cardiovascular Diseases    

The increasing prevalence of heart valve disorders such as valve stenosis and regurgitation is a significant driver for the prosthetic heart valve market. Factors contributing to this rise include the global aging population and the prevalence of unhealthy lifestyles leading to conditions like hypertension and obesity. For instance, a 2023 article from the National Center for Biotechnology Information (NCBI) indicated that valvular heart disease affects approximately 2% of the U.S. population, based on estimates from the American Heart Association. As these conditions progress, they often result in the deterioration of heart valves, necessitating surgical intervention. Prosthetic heart valves play a crucial role in managing severe cases where the native valve function is compromised, providing patients with improved quality of life and extended longevity. The growing awareness of cardiovascular health and advancements in diagnostic capabilities further contribute to early detection and treatment, fueling the demand for prosthetic heart valves worldwide.            

• Growing Aging Population      

The demographic shift towards an older population globally is boosting demand for prosthetic heart valves. As people age, the risk of developing cardiovascular diseases increases, including degenerative conditions affecting heart valves. This demographic trend translates into a larger pool of patients requiring heart valve replacement surgeries to restore proper cardiac function. Prosthetic heart valves offer effective solutions for elderly patients who may not be suitable candidates for other treatments due to age-related health concerns. Moreover, advancements in medical care and improved life expectancy drive the need for durable and reliable prosthetic heart valve options.

Opportunities

• Development of Transcatheter Heart Valves   

The development of transcatheter heart valve technologies represents a significant advancement in cardiac care, offering less invasive alternatives to traditional surgical valve replacement. These minimally invasive procedures allow for the replacement of diseased heart valves without open-heart surgery, reducing recovery times, complications, and hospital stays. Transcatheter heart valves are particularly beneficial for high-risk patients who may not tolerate traditional surgery well. This technological innovation expands treatment options and improves accessibility to valve replacement therapies for a broader patient population. Continued research and development in transcatheter valve technologies are expected to create new opportunities for market growth and innovation in cardiac surgery.  

• Technological Advancements in Cardiac Surgery    

Technological advancements in cardiac surgery have revolutionized the treatment landscape for heart valve disorders by enhancing surgical techniques and prosthetic valve materials. Minimally invasive approaches, such as transcatheter valve replacement and robotic-assisted surgery, have significantly improved patient outcomes compared to traditional open-heart procedures. These techniques involve smaller incisions, reduced trauma to surrounding tissues, and shorter recovery times, allowing patients to return to normal activities sooner. These innovations not only broaden the eligible patient population by including higher-risk patients who may not tolerate extensive surgery but also enhance overall surgical precision and long-term outcomes, creating new market opportunities.

Restraints/Challenges

• High Cost of Prosthetic Heart Valves     

The high cost associated with prosthetic heart valve procedures, particularly mechanical valves requiring lifelong anticoagulation therapy, presents a significant barrier to adoption, particularly in lower-income regions. The expense not only includes the initial implantation procedure but also ongoing medical management and monitoring. This financial burden limits access to prosthetic heart valve treatments for patients in regions with limited healthcare resources or inadequate insurance coverage, challenging the market growth.      

• Risk of Complications of Surgeries   

Prosthetic heart valve replacement surgeries carry inherent risks of complications such as valve thrombosis, infection, and structural deterioration over time. These potential complications necessitate meticulous patient selection, thorough pre-operative evaluation, and vigilant post-operative care to minimize risks and ensure optimal outcomes. The complexity of managing these risks can deter some patients and healthcare providers from choosing valve replacement surgery as a treatment option.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Prosthetic Heart Valve Market Scope

The market is segmented on the basis of type, product, technology, and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Transcatheter Heart Valve
• Tissue Heart Valve
• Mechanical Heart Valve

Product

• Repair Products
• Mitral Valve Repair Devices
• Tricuspid Valve Repair Devices

Technology

• Biological Valve
• Decellularized Valve

End Use

• Hospitals
• Ambulatory Surgical Centres
• Specialty Clinics
• Others

Prosthetic Heart Valve Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, type, product, technology, and end use as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to advanced healthcare infrastructure, strong research and development capabilities, and widespread integration of cutting-edge medical technologies within the Prosthetic Heart Valve Market. Leading manufacturers significantly enhance production capacities on a global scale.

Asia-Pacific is expected to witness significant growth during the forecast period due to the introduction of innovative products incorporating technical advancements, increasing demand for minimally invasive devices, and rising incidence of cardiac valve disorders. The expanding populations and economies of countries like India and China are expected to further bolster this growth trajectory.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Prosthetic Heart Valve Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Abbott (U.S.)
• Medtronic (U.S.)
• Boston Scientific Corporation (U.S.)
• Edwards Lifesciences Corporation (U.S.)
• LivaNova PLC (U.K.)
• Cryolife, Inc. (U.S.)
• Lepu Medical Technology (Beijing) Co., Ltd. (China)
• Braile Biomédica (Brazil)
• SYMETIS (Switzerland)
• JenaValve (Germany)
• Colibri Heart Valve (U.S.)
• Cardiac Dimensions Inc. (U.S.)
• Cardiosolutions, Inc. (U.S.)
• Medtentia AB (Sweden)
• MitralSolutions, Inc. (U.S.)
• On-X Life Technologies, Inc. (U.S.)
• Sadra Medical, Inc. (U.S.)
• Sorin S.p.A. (Italy)
• St. Jude Medical, Inc. (U.S.)
• ValveXchange, Inc. (U.S.)

Latest Developments in Prosthetic Heart Valve Market

• Em fevereiro de 2024, a Edwards Lifesciences Corporation apresentou o sistema de substituição da válvula tricúspide EVOQUE como a primeira terapia transcateter aprovada pela Food and Drug Administration (FDA) dos EUA para o tratamento da regurgitação tricúspide (TR). O sistema está indicado para melhorar o estado de saúde em doentes com RT sintomática grave, apesar da terapêutica médica ideal (OMT), quando a substituição da válvula tricúspide é considerada apropriada por uma equipa cardíaca        
• Em março de 2023, a Abbott anunciou a aprovação da FDA para a sua válvula de tecido com stent Epic Max para tratar a regurgitação ou estenose aórtica. O Epic Max apresenta um design otimizado que visa melhorar o fluxo sanguíneo através da válvula, solidificando ainda mais a sua eficácia no tratamento de doentes com distúrbios da válvula aórtica.

SKU-2125